All News

Nobody prepared me for the hardest part of my cancer experience — the toll it would have on my 6-year-old son.

Updated trial results showed that the use of Kisqali plus fulvestrant was associated with an approximate 33% decrease in risk of death for women with HR-positive, HER2-negative advanced breast cancer.

Christine Amoroso, B.S.N., RN, OCN, figured out the best way to deliver direct-to-kidney treatment for her patients.

I used to love spending time outdoors during the warm weather, but when I started getting hot flashes after my cancer-related oophorectomy, enjoying hot days got a bit trickier.

Results from a phase 3 trial showed that the combination of Nubeqa, docetaxel and androgen-deprivation therapy significantly decreased the risk of death for men with a certain type of prostate cancer.

Since being diagnosed with breast cancer, I’ve been vigilant about reading the labels of items I buy to see if they contain carcinogens, but I never thought about the potential chemicals in my drinking water... until recently.

While a higher risk of heart issues was found in older men years after androgen-deprivation therapy, it is unknown if the risk comes from the treatment or other age-related comorbidities.

"You have to have compassion — the ability to put yourself in the patient or family’s shoes and know what they’re going through," said an oncology nurse who was a finalist for 2022 Extraordinary Healer® award.

The trial of CLR 131 (iopofosine) for relapsed/refractory Waldenstrom’s macroglobulinemia will continue, as the drug will be studied in an estimated 50 patients.

John Wayne coined the term, “the Big C,” for cancer, but I think it’s time that the capital letter C stands for something better.

Cognitive behavioral therapy has been proven to improve insomnia in cancer survivors, but research is lacking in patients who are currently undergoing treatment or who have advanced disease.

From her earliest childhood days, Tammy Allred, RN, OCN, had a vision for her future: to soothe and to heal.

An interview with Livia Szeto, B.S.N., RN, OCN, a finalist for the 2022 Extraordinary Healer® award.

Watch Dr. Thomas Hutson, Dr. Saby George, Dr. Jeff Yorio and Louise Gunter answer questions about combination therapy, during the CURE Educated Patient Kidney Cancer Summit.

Livia Szeto, B.S.N., RN, OCN, has "unparalleled" patient relationships and research skills, allowing her to provide excellent care.

Watch Louise Gunter, from Texas Oncology, discuss IO/TKI-related side effects, during the CURE Educated Patient Kidney Cancer Summit.

An interview with Margaret Campbell, B.S.N, RN, the winner of the 2022 Extraordinary Healer® award.

Not only have Margaret Campbell's, own patients benefited from her dedication, but so many patients in the United States and around the world have access to better treatments due to her contributions.

Throughout my cancer experience, I’ve relied heavily on friends and family for support. But as they are moving on and starting families of their own, I realized how much time I’ve lost to cancer.

From an osteosarcoma survivor modeling inclusivity in the fashion world to rock guitarist Paul “Bonehead” Arthurs being diagnosed with cancer, here’s what’s happening in the cancer space this week.

Watch Dr. Jeff Yorio, from Texas Oncology, discuss treatment with the combination of immunotherapy and tyrosine kinase inhibitors, during the CURE Educated Patient Kidney Cancer Summit.

After Enhertu showed promising clinical trial results, the Food and Drug Administration agreed to speed up the development and review of the drug for certain patients with unresectable or metastatic breast cancer.

Chemotherapy-induced peripheral neuropathy is a common side effect of patients undergoing cancer treatment, though many patients are not fully informed about the condition before their therapy starts.

Well-meaning comments can come off as bothersome — or even hurtful — to me as I navigate cancer.

Watch Dr. Saby George, from Roswell Park Comprehensive Cancer Center, discuss treatment with the combination of immunotherapies, during the CURE Educated Patient Kidney Cancer Summit.

For the first time in three years, CURE® welcomed 500 attendees in person and hundreds more virtually to honor the 2022 Extraordinary Healer® award recipient.

The first patient was dosed in the CLAUDIO-01 trial, analyzing SOTO102 in patients with certain types of gastric and pancreatic cancers.

From my “game-day uniform” to a playlist that made me feel ready to seize the day, here’s what helped me prepare for my days in cancer treatment.